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Summary. The prognosis for patients with high grade gliomas is poor, with a median survival of
1 year. Treatment efficacy assessment is typically unavailable until 5–6 months post diagnosis.
Investigators hypothesize that quantitative magnetic resonance imaging can assess treatment
efficacy 3 weeks after therapy starts, thereby allowing salvage treatments to begin earlier. The
purpose of this work is to build a predictive model of treatment efficacy by using quantitative
magnetic resonance imaging data and to assess its performance.The outcome is 1-year survival
status.We propose a joint, two-stage Bayesian model. In stage I, we smooth the image data with
a multivariate spatiotemporal pairwise difference prior. We propose four summary statistics that
are functionals of posterior parameters from the first-stage model. In stage II, these statistics
enter a generalized non-linear model as predictors of survival status. We use the probit link and
a multivariate adaptive regression spline basis. The hybrid Metropolis-within-Gibbs algorithm
and reversible jump Markov chain Monte Carlo methods are applied iteratively between the two
stages to estimate the posterior distribution.Through both simulation studies and model perfor-
mance comparisons we find that we can achieve higher overall correct classification rates by
accounting for the spatiotemporal correlation in the images and by allowing for a more complex
and flexible decision boundary provided by the generalized non-linear model.
Keywords: Bayesian analysis; Image analysis; Multivariate adaptive regression splines;
Multivariate pairwise difference prior; Quantitative magnetic resonance imaging;
Spatiotemporal model
1. Introduction
Our work is motivated by a need to analyse data collected from quantitative magnetic reso-
nance imaging (QMRI) studies appropriately, and to determine whether QMRI can be used
as an early predictor of treatment efﬁcacy as measured by survival for patients with malig-
nant gliomas. The data come from a pilot study of 53 high grade glioma patients (Hamstra
et al., 2005). The prognosis for patients with high grade gliomas is poor. The mortality rate,
at the time of data collection, is high with a median survival of 1 year after diagnosis (Laws
et al., 2003). Treatment is a combined approach of surgery (if possible) and radiation therapy
followed by chemotherapy. Assessment of treatment efﬁcacy is based on radiological response
approximately 8–10 weeks post therapy, or approximately 5–6 months after diagnosis (Moffat
et al., 2005; Hamstra et al., 2008). Radiological response is determined by the change in tumour
size from baseline as measured on anatomical MR images. For those with progressive disease,
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salvage therapy is given. However, it is typically too late for the salvage therapy to have any
effect in prolonging survival (Moffat et al., 2005). If treatment efﬁcacy can be assessed earlier,
salvage therapies can begin earlier or therapy can be modiﬁed.
In the pilot study, two different QMRI studies (diffusion and perfusion) and standard ana-
tomicalMRI studies were conducted at each of two time points: baseline (1week before therapy)
and 3 weeks after therapy begins. All four quantitative images were registered to the pretreat-
ment anatomical MR image via a mutual information algorithm (Meyer et al. (1997), i.e. an
afﬁne translation and rotation). Full imaging data were available on 47 of the 53 patients; there-
fore we analyse the data from these 47 patients. Tumours were identiﬁed on contrast-enhanced
T1-weighted MR images at both time points and segmented (outlined) by a radiologist. We
use the intersection of the segmented tumours as the region of interest (ROI) (Hamstra et al.,
2005, 2008; Moffat et al., 2005). Using the intersection of the segmented tumours, as opposed
to the union, avoids the potential comparison of tumour in one image with healthy tissue or
oedema in the other image thatmay occur in the symmetric difference of the segmented tumours
because of small changes in tumour volume, swelling of tissue caused by therapy and errors in
segmentation.
The apparent diffusion coefﬁcient (ADC) is a measure of the magnitude of Brownian motion
of water molecules in the extracellular space of tissue (Hamstra et al., 2005, 2008; Moffat et al.,
2005). Diffusion in biological systems is a complex phenomenon, inﬂuenced directly by tissue
microstructure. Its measurement can provide information about the organization of this struc-
ture in normal and diseased tissue (Basser and Jones, 2002). As tumour cells lyse, the ratio of
extracellular to intracellular ﬂuid increases, thus causing a temporary increase in ADC (Moffat
et al., 2005, 2006). Perfusion is a measure of tissue-speciﬁc blood ﬂow and blood volume and
reﬂects the delivery of essential nutrients to tissue (Galbán et al., 2009). It is hypothesized that
effective therapy will disrupt tumour blood supply by damaging tumour neovascularity, result-
ing in decreased tumour perfusion. Furthermore, recent studies have suggested that QMRI can
be used for early prediction of therapeutic efﬁcacy. Early changes detected inmean tumourADC
values were ﬁrst found to be correlated with treatment response in rodent tumour models (Ross
et al., 1994; Zhao et al., 1996; Chinnaiyan et al., 2000). Previous studies investigating perfusion
MRI for tumour diagnosis and response monitoring relied on the whole-tumour mean value as
the summary statistic of the perfusion maps for quantiﬁcation of haemodynamic parameters,
with varying success (Young et al., 2007; Law et al., 2007). The functional diffusionmap (FDM),
a voxel-by-voxel approach, was recently reported as an early quantitative biomarker for clinical
brain tumour treatment outcome (Hamstra et al., 2005, 2008; Moffat et al., 2005). Galbán et al.
(2009) have also shown that the functional perfusion map based on perfusion MRI (obtained
in the same way as the FDM) is predictive of overall survival. However, both the FDM and
the functional perfusion map treat voxels as independent observations, thus ignoring spatial
structure in the images. Treating the data as independent observations may lead to incorrect
variance estimates and invalid inference. Our work is motivated by all of these studies and aims
to build a statistically robust and predictive model for treatment efﬁcacy based on both the
ADC and the relative cerebral blood ﬂow (RCBF) (which is a measure of perfusion; Galbán
et al. (2009)) images. An axial slice of a registered ADC image, an RCBF and a T1-weighted,
contrast-enhanced MR image are shown in Fig. 1.
We propose a joint, two-stage Bayesian predictive model. In the ﬁrst stage, we smooth the
images (two images at each of two time points) by using a multivariate pairwise difference prior
that models the spatiotemporal correlation in the images. The pairwise difference prior was
ﬁrst introduced by Besag (1993). It is a member of the class of pairwise interaction Markov
random-ﬁeld models and captures general and local characteristics of the image. A priori, it
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Fig. 1. Single axial slice of pretreatment MRI data (the tumour is visible in all three images; it is located
at roughly voxel (100,80) just below the left ventricle): (a) diffusion MR image; (b) perfusion MR image; (c)
T1-weighted contrast-enhanced MR image
assumes that the mean values of neighbouring voxels are positively correlated. We extend the
pairwise difference prior to the multivariate setting. We then propose four summary statistics
that are functionals of the parameters in stage I. The statistics enter the second-stage model as
predictors of 1-year survival status. The second-stage model is a generalized non-linear model
(GNLM) that was proposed by Holmes and Denison (2003). The GNLM uses a probit link,
for computational efﬁciency, and a Bayesian multivariate adaptive regression spline (BMARS)
basis. The MARS model was introduced by Friedman (1991). The BMARS basis allows the
predictors to enter the GNLM model non-linearly, thus allowing for a very ﬂexible decision
boundary. The twomodels are ﬁtted jointly and themodel is validated via cross-validated predic-
tion. Algorithmically, the models are joined by iterating between the two stages in a generalized
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Markov chain Monte Carlo (MCMC) simulation (Metropolis-within-Gibbs updates in stage I
and a hybrid reversible jump MCMC and Gibbs updates of hyperparameters in stage II).
Comparedwith currentmethods, our jointmodel has several new features and improvements.
In the ﬁrst stage, our model
(a) accounts for spatiotemporal correlation in the images, as well as the correlation between
the ADC and RCBF images,
(b) increases the signal-to-noise ratio by smoothing the images and
(c) reduces the data dimension via subject level summary statistics.
In the second stage, our model allows for a more ﬂexible classiﬁcation boundary than that
allowed by the standard linear systematic component of a generalized linear model. The joint
model that we propose propagates the sampling error from stage I into stage II. We adopt the
Bayesian paradigm for estimating and predicting outcomes. Furthermore, model uncertainty is
captured by model averaging.
This paper is organized as follows. In Section 2, we ﬁrst outline, at a high level, our joint
model and then specify the two stages of the model and propose our model evaluation strategy
that we have adopted. The pilot study data are then analysed in Section 3. We show that our
model outperforms simpler models in Section 4. The paper concludes with a discussion, sum-
marizing the strengths and limitations of our approach. For brevity, results from simulation
studies and sensitivity analyses can be found in a supplementary Web-based material (SWBM)
document that is available at http://www.bepress.com/umichbiostat/paper83 or
by contacting the authors. Detailed mathematical derivations of the posterior distributions,
details of the algorithm and pseudocode are also provided in the SWBM.
2. Bayesian joint model
To begin, we brieﬂy describe the joint model. Let Y denote the set of all images for all subjects
and let Z denote the 1-year survival status (1, dead; 0, alive) vector. LetΩ=Ω1 ∪Ω2 denote the
set of all model parameters whereΩ1 is the set of stage I model parameters and predictive values
andΩ2 is the set of stage II model parameters. We further note that the set (over all subjects) of
all summary statistics, X , calculated in stage I is a functional vector of Ω1 and that Z depends
on Ω1 only through X =F.Ω1/. The posterior distribution can be factored as
π.Ω|Y ,Z/∝π.Y|Ω1/π.Ω1/π.Z|Ω1,Ω2/π.Ω2/: .1/
We shall use π.Z|Ω1,Ω2/, π.Z|Ω/ and π.Z|X ,Ω2/ interchangeably depending on the context.
We draw from the posterior (1) via MCMC simulation by iteratively drawing between the full
conditional distribution of Ω1,
π.Ω1|Y ,Z,Ω2/∝π.Y|Ω1/π.Ω1/π.Z|Ω1,Ω2/, .2/
and the full conditional distribution of Ω2,
π.Ω2|Z,Ω1/∝π.Z|Ω1,Ω2/π.Ω2/: .3/
The full conditionals in expressions (2) and (3) are easily derived fromexpression (1) and repeated
use of Bayes’s theorem.We assume, a priori, thatΩ1 andΩ2 are independent. However, they are
dependent in the posterior. From equations (2) and (3), the full conditional distribution of Ω1
depends on Z,Y andΩ2 and the full conditional distribution ofΩ2 is conditionally independent
of Y given Ω1.
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The remainder of this section is broken up into four subsections. In Section 2.1 we deﬁne the
multivariate pairwise difference prior model, in Section 2.2 we deﬁne the GNLM and then in
Section 2.3 we give an overview of how we sample from the joint posterior distribution that is
speciﬁed in expression (1). In the last subsection, Section 2.4, we describe how we evaluate our
model.
2.1. Stage I
In this subsection, patients’ subscripts are suppressed to reduce the notational burden. Tumour
voxels (i.e. volume elements—a cube) are indexed by i=1, 2, . . . ,n, where the tumour size n (i.e.
the size of the tumour ROI deﬁned in Section 1) ranges from 770 to 20380 voxels with a mean of
6143 and standard deviation of 4721. Two voxels, i and i′, that share a common face are called
neighbours, denoted by i∼ i′. Let Ni = {i′ : i′ ∼ i} denote the set of neighbours of voxel i with
|Ni| denoting the number of neighbours. Let Yith represent the image intensity at voxel i, time
t =1, 2 (baseline and week 3 respectively) and image type h (h=1, diffusion; h=2, perfusion).
The vector of image intensities at voxel i is Yi = .Yi11,Yi12,Yi21,Yi22/T. We split Yi into two
subvectors by time: Yit = .Yit1,Yit2/T. Furthermore, let Y = .YT1 , . . . ,YTn /T. Each Yith is mea-
sured with error with mean μith. Let μi = .μi11,μi12,μi21,μi22/T with corresponding subvectors
μit = .μit1,μit2/T. Let μ= .μT1 , . . . ,μTn /T. Note that the components in Yi are correlated with
covariance Σ.
We extend Besag’s (1993) pairwise difference prior model to the multivariate setting. First,
[Y|μ,ΣÅ]∼N.μ,ΣÅ/, .4/
where ΣÅ =diag.Σ/—a block diagonal matrix with Σ along the main diagonal. The prior dis-
tribution of the mean vector μ is
π.μ|Ψ/∝ exp
{
−0:5∑
i∼i′
.μi −μi′/TΨ−1.μi −μi′/
}
:
Spatial correlation in the image is modelled through the diagonal elements of the 4×4 covari-
ancematrixΨ. The off-diagonal elements ofΨ account for temporal correlationwithin an image
type, correlation between image types at a particular time and correlation over time and across
image types. The covariance matrix Σ accounts for residual covariances. In equation (4), we
assume the normal distribution for the noise in the images, which is commonly used and has
been justiﬁed in Lei and Udupa (2002) and Liang et al. (2000).
A priori, Σ and Ψ are assigned inverse Wishart distributions: W−1.I4, 5/. The scale matrix I4
is the 4×4 identity matrix and the number of degrees of freedom is 5. The degrees of freedom
can be regarded as the a priori sample size. Given the large n, this results in a rather weak
prior.
2.1.1. Predicting tumour response under the ‘null’
Ideally we would compare the observed tumour response with its counterfactual: tumour
response given no treatment. Given that this is impossible, our summary statistics will be based
on comparing the observed tumour response with the predicted tumour response in the contra-
lateral hemisphere of the brain under the assumption that the change in ADC or RCBF values
in healthy tissue in the contralateral brain and those of tumour in the contralateral brain, if they
could be observed, are similar. In the contralateral brain the healthy tissue receives a low dose
of radiation and little damage from chemotherapy because of the blood–brain barrier which
blocks large chemotherapy molecules. Thus, the healthy tissue in the contralateral brain is pro-
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tected from therapy and diffusion and perfusion are stable over the short time period between
imaging sessions. We deﬁne a healthy tissue ROI in the contralateral brain. The healthy tissue
ROI is obtained by reﬂecting the tumour ROI, approximately about the midline of the brain, to
the contralateral hemisphere. We then ensure, visually, that the healthy tissue ROI lies within
the grey matter of the brain (some white matter is ﬁne). If the healthy tissue ROI intersects the
ventricles, meninges or skull, we manually shift the ROI, to avoid this overlap (details can be
found in the SWBM). We now describe how we predict tumour response in the healthy tissue
ROI, which we refer to as the null response.
First we build a multivariate pairwise difference prior model for the healthy tissue data in the
healthy tissue ROI. The model is identical to that described above with the following notational
changes. For healthy tissue, in the healthy tissue ROI, let Wi denote the image intensities for
voxel i with mean vector νi. The covariance of the Wi will be denoted Δ and the covariance
of the mean vector νi will be denoted Ω. The number of voxels in the healthy tissue ROI is
also n. Denote the set of voxels in the healthy ROI by H. We extend the healthy tissue ROI by
a one-voxel-thick shell and denote the set of voxels in this shell by S. Without this extension,
Y˜i2 and μ˜i2 are not identiﬁable (see equations (5) and (6) below and section 5 in the SWBM).
Let ns denote the number of voxels in the shell and let ne =n+ns be the number in the extended
ROI. Let Nei ={i′ : i′ ∼ i} denote the set of neighbours of voxel i in the extended ROI and |Nei |
denote the number in this set.
Now, to predict the tumour null response, we translate the tumour baseline values Yi1 to
the healthy tissue ROI, using the same reﬂection and shift that created the healthy tissue ROI.
We partition the 4× 4 covariance matrices into four 2× 2 matrices. The multivariate pairwise
difference prior for prediction is((
Yi1
Y˜i2
)∣∣∣∣
(
μi1
μ˜i2
)
,
(
Δ11 Δ12
Δ21 Δ22
))
∼N
{(
μi1
μ˜i2
)
,
(
Δ11 Δ12
Δ21 Δ22
)}
.5/
where Y˜i2 = .Y˜ i21, Y˜ i22/T is the predicted null response at time point 2 and μ˜i2 is its mean. The
μi1 are obtained from the posterior distribution of the tumour multivariate pairwise difference
prior model and the covariances from the healthy tissue multivariate pairwise difference prior
models. Let (
μÅi1
μ˜Åi2
)
=|Nei |−1
{ ∑
i′∈Nei ∩S
(
0
νi′2
)
+ ∑
i′∈Nei ∩H
(
μi′1
μ˜i′2
)}
: .6/
The prior for the mean vector in expression (5) is
((
μi1
μ˜i2
)∣∣∣∣
(
μÅi1
μ˜Åi2
)
,
(
Ω11 Ω12
Ω21 Ωi22
))
∼N
{(
μÅi1
μ˜Åi2
)
, |Nei |−1
(
Ω11 Ω12
Ω21 Ω22
)}
.7/
where the covariances are obtained from the posterior of the healthy tissuemultivariate pairwise
difference prior model. The covariances taken from the posterior of the healthy tissue multi-
variate pairwise difference prior model describe the spatiotemporal relationship between the
baseline tumour ADC or RCBF values and the predicted values under our assumption that
tumour changes would be similar to healthy tissue changes in the environment of the contra-
lateral hemisphere. We need to ensure that Σ11 and Δ11 are similar as well as Ψ11 and Ω11
as these describe the baseline residual covariances and spatial covariances. If they are much
different, the inequality in the baseline covariances may result in biased predictions. We may be
tempted to replaceΔ11 withΣ11 in expressions (5) andΩ11 withΨ11 in expression (7); however,
there is no guarantee that the resulting covariance matrices would be positive deﬁnite. After
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ﬁtting our model to the data we investigated whether these assumptions hold by comparing the
posterior expected values of these leading submatrices. To compare them, we computed the rel-
ative root-mean-squared difference between the three unique elements in the leading 2×2 sub-
matrices, where the mean is computed over draws from the posterior (see details in the SWBM,
section 1.1). The relative root-mean-squared difference between the leading 2×2 submatrices
of Δ and Σ (relative to Δ) is 0.038 (standard deviation 0.029) and that between the leading
submatrices of Ω and Ψ (relative to Ω) is 0.039 (standard deviation 0.018)—both small relative
differences—hence we feel that this assumption is justiﬁed in our model.
Now we explicitly deﬁne the stage I parameter set Ω1 and, at the same time, add a subject-
speciﬁc index, j. Gather all parameters and predictive values into a set of parameters for subject
j: Ω1j ={{μi,j}nji=1, {νi,j}
nej
i=1,Σj,Ψj,Ωj,Δj, {Y˜i2,j}
nj
i=1,{μ˜i2j}
nj
i=1}. Then Ω1 =∪jΩ1j.
2.1.2. Summary statistics
The summary statistics are based on comparing the observed tumour response with the pre-
dicted tumour response under the null hypothesis. Previous work suggests that the mean change
in tumour ADC values is not predictive of treatment efﬁcacy in humans (Chenevert et al., 2000;
Moffat et al., 2005). Empirically, however, the baseline tumour ADC (RCBF) histogram and
the week 3 tumour ADC (RCBF) histogram are notably different. This gave us the idea to
investigate whether the Kullback–Leibler divergence (Kullback and Leibler, 1951) between the
posterior and predictive draws of μi2h and μ˜i2h,h=1, 2 respectively, would be good predictors
of treatment efﬁcacy. Speciﬁcally, we draw μi2h from its full conditional posterior for all i in
the tumour ROI and create a histogram and draw μ˜i2h from its full conditional posterior for
all i, create a histogram and then compute the Kullback–Leibler divergence between these two
histograms (see details in the SWBM, section 1.2). We denote the statistics as dKLD for the
diffusion image and pKLD for the perfusion image.
Hamstra et al. (2005, 2008) and Moffat et al., 2005) have demonstrated that the FDM, which
is a statistical approach for segmenting tumours into regions of response and non-response, on
the basis of a deﬁned upper threshold of ADC change following therapy, is a good biomarker
for predicting early tumour response to therapy (this threshold is basically an upper prediction
limit of the regression slope of the week 3 tumour ADC values regressed on the baseline ADC
values). The FDM approach is based on the rationale that early ADC changes due to therapy
are heterogeneous within the tumour. Parts of the tumour respond to therapy and show an
increase in ADC, whereas other regions show no change or even a decrease in ADC. However,
successful therapy should result in tumour cells lysing with a corresponding increase in ADC:
thus the rationale for deﬁning an upper threshold. Furthermore, a successful treatment should
result in a decrease in RCBF, as discussed in Section 1. However, again, tumour response is
heterogeneous and the mean change is minimal, whereas changes in the tails of the distribution
aremore pronounced. Inspired by the FDM,we sought statistics that summarize the proportion
of extreme expected values, μi2, in the tumour response relative to the conditional distribution
(SWBM, formula (29)) of means of predicted null tumour voxel responses. We propose two
additional summary statistics: the conditional diffusion statistic cDS and the conditional per-
fusion statistic cPS. The ﬁrst, cDS, is deﬁned as the proportion of tumour voxels that have a
mean response that is greater than the 0.975-quantile of the conditional distribution (SWBM,
formula (29)) of the same voxel under the null assumption:
cDS=n−1
n∑
i=1
I[μi21 >q0:975.μ˜i21/],
where I[·] is the indicator function and q0:975.μ˜i21/ is the 0.975-quantile of the conditional
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posterior distribution of μ˜i21. The summary measure cPS is similarly deﬁned:
cPS=n−1
n∑
i=1
I[μi22 <q0:025.μ˜i22/],
where q0:025.μ˜i22/ is the 0.025-quantile of the conditional posterior distribution of μ˜i22.
2.2. Stage II
For stage II, we borrow the GNLM with a BMARS basis (GNLM–BMARS model) that was
proposed by Holmes and Denison (2003) to predict patients’ 1-year survival status. For patient
j, let Xj = .Xj1, . . . ,Xj4/T denote the vector of the summary statistics that is obtained in stage I.
Hence X =∪j {Xj}j. Let Zj index the survival status of patient j, with Zj =1 representing the
death of patient j within 1 year, and Zj = 0 otherwise, for j = 1, . . . ,M. Set Z= .Z1, . . . ,ZM/.
The set of all GNLM–BMARS parameters, Ω2, will now be subscripted by K , the number
of BMARS bases, as the number of bases is treated as a parameter to be estimated and the
number of parameters inΩ2K depends on K. All parameters inΩ2K will be deﬁned shortly. The
GNLM–BMARS model with K basis functions is
π.Zj =1|Xj,Ω2K/=g.ηjK/, ηjK =
K∑
k=0
βkBk.Xj/,
Bk.Xj/=
⎧⎨
⎩
1, k=0,
Lk∏
l=1
[slk.Xjwlk − tlk/]+ , k=1, 2,. . . , K.
.8/
The link function g could be the cumulative distribution function from any of the commonly
used distributions for modelling binary data such as the logistic, normal or extreme value distri-
butions. Owing to the ﬂexibility in the decision boundary that is afforded by the BMARS basis,
we argue that the choice of link function is not crucial. Thus, for computational efﬁciency and
simplicity, we use the probit link function, g.·/=Φ.·/, where Φ is the standard normal cumula-
tive distribution function. The function [·]+ =max.0, ·/. K is the number of basis functions in
the model. Lk is the degree of interaction in basis function Bk.·/. For our application, we set the
highest order of interaction to 2. Thus, onlymain effects and two-way interactions are allowed to
enter the model. Estimating higher order interactions with any certainty would require a larger
amount of data owing to the curse of dimensionality (Denison et al., 2002). The variable slk is
a sign indicator, taking values in {−1, 1}; tlk is the location of the spline knot that is associated
with the covariate indexed by wlk ∈{1, 2, 3, 4}. Further tlk is restricted to the set of covariate val-
ues {X1wlk , . . . ,XMwlk} and allwlk are distinct for each k (i.e. each basis function is at most linear
in any one variable). Consult Holmes and Denison (2003) and Denison et al. (2002), chapter
4, or the SWBM for further details. Let βK = .β0, . . . ,βK/T where β0 is the model intercept.
Also, let LK ={L1, . . . ,LK}, sK ={s11, . . . , sLKK}, wK ={w11, . . . ,wLKK}, tK ={t11, . . . , tLKK}
and ΘK ={K, sK,wK, tK,LK}. Then Ω2K =ΘK ∪{βK}.
We specify non-informative prior distributions for all parameters,
π.Lk =1/=π.Lk =2/= 12 ,
π.w1k =w|LK =1/= 14 , w=1, 2, 3, 4,
π[.w1k,w2k/= .w,w′/|LK =2]= 16 , .w,w′/= .1, 2/, .1, 3/, .1, 4/, .2, 3/, .2, 4/, .3, 4/,
π.tlk =Xjwlk |wlk/=1=M, j =1, . . . ,M,
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π.slk =−1/=π.slk =1/= 12 ,
[βK|v,K]∼N.0, vIK+1/, [v−1]∼gamma.0:001, 0:001/,
with one exception: [K|λ]∼Poisson.λ/ and [λ]∼ gamma.1, 0:2/. We assess the effect of this
prior on classiﬁcation results in the SWBM.
2.3. Sampling from the joint posterior
Nowwe outline howwe sample from the joint posterior given in expression (1). Formore details
and derivations, consult the SWBM.
We begin with the sampling of stage I parameters. We sample parameters μi,j, νi,j, μ˜i2,j, Σj,
Ψj, Δj and Ωj for i=1, . . . ,nj and j =1, . . . ,M from their full conditional distributions via a
hybrid Metropolis-within-Gibbs algorithm. Both Ψj and Σj are drawn directly from their full
conditionals (inverse Wishart distributions). The remaining parameters are drawn from their
full conditionals via Metropolis–Hastings updates (Hastings, 1970). Full details are provided in
the SWBM, section 1. We note here that all parameters in a stand-alone multivariate pairwise
difference priormodel can be updated by aGibbs algorithm.However, owing to the joint nature
of our full model, all stage 1 parameters other thanΨj andΣj are linked to stage II through the
summary statistics and thus require Metropolis-within-Gibbs updates as the full conditionals
no longer have a nice distributional form.
Now we outline our posterior sampling algorithm for stage II parameters. In probit regres-
sion models, the posterior distribution can be simulated by a Metropolis–Hastings algorithm.
However, to simplify computation,Albert andChib (1993) derived a data augmentation scheme
which relies on the latent variable model representation of a binary variable. This approach
greatly simpliﬁes sampling from the posterior distribution as the model is transformed from a
probit regression model into an equivalent linear model; thus the parameter vector βK can be
drawn from its full conditional as opposed to the Metropolis–Hastings algorithm.
We introduce a continuous latent vector d= .d1, . . . ,dM/T.Deﬁne the conditional distribution
of Zj given dj by
π.Zj =1|dj/=
{
1 ifdj >0,
0 ifdj0: .9/
The full conditional distribution of dj is straightforward to derive (see the SWBM and Holmes
and Denison (2003)) and is
[dj|Zj = zj,Xj,Ω2K]∼
{
N.ηjK, 1/ truncated at the left by 0 if zj =1,
N.ηjK, 1/ truncated at the right by 0 if zj =0: .10/
Wedraw dj, j=1, . . . ,M, fromdistribution (10).We thendrawβK from its full conditional distri-
bution: [βK|d, v,ΘK,X ]∼N.mÅK,VÅK/, where VÅK ={.vIK+1/−1 +BTKBK}−1 and mÅK =VÅKBTKd.
Standard conjugacy results state that the full conditional distribution of v−1 is [v−1|βK,K]∼
gamma{0:001+0:5.K+1/, 0:001+0:5βTKβK}.
All parameters contained in ΘK are updated via the reversible jump MCMC algorithm
(Green, 1995). Since K is random, the dimension ofΘK varies as well as the column dimension
of thematrix of BMARSbases,BK, and the dimension of the vector βK. At each iteration of the
algorithm, we randomly (with equal probability) choose to add a new basis function (birth step)
or to remove one of the existing basis functions (death step). Thus, covariates (summary statis-
tics) and any two-way interactions enter the model via these birth and death steps. Details of the
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reversible jumpMCMCalgorithm and pseudocode for sampling from the posterior distribution
of our joint model are given in the SWBM.
2.4. Model evaluation
The traditional way to evaluate classiﬁcation models is by randomly partitioning the data into
a training set for model building and a test set for model evaluation. However, because of the
small sample size in our data set, we evaluate our proposed joint model via cross-validation.
To implement cross-validation, a straightforward, but computationally expensive, approach is
to run the algorithm multiple times with one observation left out each time. Instead, we adopt
the importance sampling approach that was proposed by Gelfand et al. (1992) whereby one
need only to estimate the posterior distribution of the parameters given the full data set and
then by importance sampling compute the predictive probability that Zj =1 given Z{−j} and Y
for subject j where Z{−j} denotes all observations except that of subject j. Let Ω
.t/
2 denote the
value of Ω2K from the tth draw from the posterior and that of Ω1 by Ω
.t/
1 . The cross-validated
posterior predictive probability is estimated by MCMC output (see the SWBM) and is given by
π.Zj =1|Z{−j},Y/=
T∑
t=1
π.Zj =1|Ω.t/1j ,Ω.t/2 /=π.Zj = zj|Ω.t/1j ,Ω.t/2 /
T∑
t=1
1=π.Zj = zj|Ω.t/1j ,Ω.t/2 /
, .11/
where zj is the observed value of Zj. We assume that the losses that are incurred by a false
negative and a false positive prediction are equal. Thus, if π.Zj = 1|Z{−j},Y/ 0:5, then the
cross-validated prediction of Zj equals 1 and 0 otherwise.
Although not part of model evaluation, here is a good place to discuss the predictive decision
boundary. Theoretically, we could use the predictive distribution, π.Znew = 1|Ynew,Z,Y/, to
deﬁne the decision boundary by varying Ynew over the space of all images. Obviously this is too
daunting a task. Instead we shall deﬁne the conditional predictive decision boundary in terms
of the summary statistics. This decision boundary is a hypersurface in R4—the covariate space.
It is deﬁned as all solutions, Xnew, to the posterior predictive probability
1
2 =π.Znew =1|Z,Xnew/=
∫
π.Znew =1|Xnew,Ω2K/π.Ω2K|Z,Ω1/dΩ2K:
We cannot visualize this decision boundary either as the dimension is 4. Therefore, to visualize
the decision boundary, we shall marginalize over pairs of covariates and plot the marginal pre-
dictive probability map as a function of the remaining pair of covariates by discretizing the
marginal covariate space into a grid of values. The marginal decision boundary, then, is a curve
in two-dimensional space (Fig. 2).
We note here that at each iteration the number of BMARS bases may change; thus implicit
in the estimation of the cross-validated predictive probability and in building the marginal
probability maps we average over all potential BMARS models. By doing so, we account for
model uncertainty in our results along with the uncertainty in the model parameters and thus,
inductively, the uncertainty in the covariates X (Raftery et al., 1996).
3. Results
Stage I is computationally much more expensive than stage II owing to the large number of
voxels, n, in each patient’s tumour. We run the algorithm (stage I and stage II combined) for
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100000 iterations. In each iteration,we oversample (10:1) draws from the posterior of the stage II
parameters. Stage I takes around 20 h for all 47 patients, whereas stage II takes 5 min. The algo-
rithm is programmed in C and implemented on a 3.0-GHz Mac Xserve computer. The ﬁrst
50 000 draws are discarded as burn-in. By visual inspection of the trace plots of the (ﬁxed
dimension) parameters, the burn-in is sufﬁcient and the chain is sampling from the posterior
(stationary) distribution.
Wecalculate the cross-validated correct classiﬁcation rateCCRcv—theproportionof correctly
predicted survival statuses—thepositive predictive valuePPVcv—theprobability of deathwithin
1 year conditional on prediction of death within 1 year—and the negative predictive value
NPVcv—the probability of survival longer than 1 year given a prediction of survival longer
than 1 year. The results are CCRcv =0:787 (37/47), PPVcv =0:813 (13/16) and NPVcv =0:774
(24/31) (Table 1, ﬁrst row). Investigators are interested in therapy intervention or modiﬁcation
if the model accurately predicts death within 1 year. Therefore, PPVcv is of greater interest than
NPVcv.
In Fig. 2 we display the six bivariate marginal predictive probability maps. On each map
is the marginal decision boundary separating the space of covariates into two regions based
on whether π.Znew = 1|Z,Xnew/ > 0:5. Also shown in Fig. 2 are the posterior means of the
covariates for all 47 subjects. The triangles represent those subjects who died before 1 year,
and the circles represent those who lived longer than 1 year. The probabilities in the maps are
π.Znew =1|Z,Xnew/ marginalized over the six combinations of pairs of covariates. It is evident
that the marginal decision boundaries are quite complex. From Fig. 2 we see that, marginally,
small values of dKLD and cDS are associated with poor survival and that large values of pKLD
are also associated with poor survival. There are also substantial interactions between cPS and
dKLD, between dKLD and cDS and between pKLD and dKLD. In general, the overall gross
pattern of increases in the dKLD- and cDS-statistics are predictive of longer survival—conso-
nant with what our colleagues hypothesized. However, the overall gross pattern of decreases in
the pKLD- and cPS-statistics are predictive of shorter survival—dissonant with that hypothe-
sized. One plausible explanation provided by our colleagues is that a reduction in RCBF creates
a hypoxic environment within the tumour and hypoxia is known to be protective against radia-
Table 1. Model comparisons†
Model CCRcv‡ PPVcv§ NPVcv§§
Bayesian joint model 0:787 .37=47/ 0:813 .13=16/ 0:774 .24=31/
Separate models (two-stage model) 0:830 .39=47/ 0:853 .15=18/ 0:827 .24=29/
Separate models (stage I + probit) 0:617 .29=47/ 0:572 .11=20/ 0:667 .18=27)
Bayesian joint model 0:723 .34=47/ 0:733 .11=15/ 0:719 .23=32/
Single model (stage II only) 0:638 .30=47/ 0:600 .9=15/ 0:656 .21=32/
†Upper part, comparisons based on all four statistics: ﬁrst row, our proposed joint model;
second row, separate two-stage model (not joint) (the second-stage model (GNLM–
BMARS) runs conditional on the posterior expectations of the summary statistics from
stage 1); third row, separate two-stage model (the second-stage model is a standard probit
regression model); summary covariates are ﬁxed at their posterior expectations from stage
I. Bottom part, comparisons using only the two KLD-statistics: fourth row, our proposed
model; ﬁfth row, summary statistics computed on observed data (GNLM–BMARS runs
conditional on ‘observed’ dKLD and pKLD).
‡Correct cross-validated classiﬁcation rate.
§Cross-validated positive predictive value.
§§Cross-validated negative predictive value.
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tion damage. However, we caution that the exact mechanism is unknown and that it warrants
further investigation (Galbán et al., 2009).
The baseline prognostic factors age, type of surgery,Karnofsky performance score, pathology
grade and tumour size were also included in stage II as covariates. However, their inclusion did
not increase the overall correct classiﬁcation rate and each was included in the model less than
20% of the time (either as main effects or in an interaction term).
Each of the four summary statistics were included in the joint model as either a main effect or
as an interaction term a high percentage of the MCMC draws (dKLD, 95.9%; pKLD, 90.5%;
cDS, 81.1%; cPS, 84.3%). This indicates their importance in predicting survival. Both dKLD
and pKLD appear to be slightly stronger predictors than either cDS or cPS on the basis of the
amount of time spent in the model.
4. Model assessment
4.1. Comparison with simpler models
Our ﬁrst comparison is with two separate models (i.e. not modelled jointly). The image data are
ﬁtted with our multivariate pairwise difference prior model. The posterior means of the sum-
mary statistics are treated as ﬁxed known values and used as covariates in ourGNLM–BMARS
model. Thus the only difference between this procedure and our joint model is that our joint
model accounts for the uncertainty in the summary statistics. Using point estimates, such as the
posterior means, of the summary statistics as covariates in stage II results in overly optimistic
prediction errors (see, for example, Little and Rubin (2002)). Ignoring the sampling variability
in stage I, two additional patients are correctly classiﬁed (Table 1, second row). The posterior
means of the summary statistics for these patients are near the decision boundary and happened
to fall on the correct side, whereas the maximum a posteriori probability estimate was on the
other side. Accounting for the variability in these random statistics, therefore, is necessary for
robust prediction.
Our second comparison is again with two separate models. We estimate the posterior means
of the summary statistics from our multivariate pairwise difference prior model. These point
estimates are then treated as ﬁxed known covariates and put into a standard probit regres-
sion model (Table 1, third row). Both main effects and interaction terms are allowed in the
probit regressionmodel. The Bayesian information criterion is used formodel selection. Correct
prediction from our joint model is much higher even though uncertainty in the covariates is
ignored, as well as model uncertainty, in the separate multivariate pairwise difference prior plus
probit regression model. The extra ﬂexibility that is afforded by the BMARS basis has a large
effect on prediction.
Our ﬁnal comparison illustrates the beneﬁts of the spatiotemporal modelling in stage I by
comparing our results with those based on the observed images. Since the cDS- and cPS-
statistics rely on the conditional distribution of tumour response under the null hypothesis,
it is not possible to derive these summary statistics on the observed images as we have no
model to use to predict tumour null response. Thus, this comparison uses only dKLD and
pKLD. We estimate dKLD and pKLD using the observed images by calculating the Kullback–
Leibler divergence between observed tumour response and observed healthy tissue response
(in the contralateral hemisphere) at week 3 and plugging these statistics into our GNLM–
BMARS model as ﬁxed covariates. Cross-validation results are shown in the bottom half of
Table 1, fourth and ﬁfth rows. Spatiotemporal modelling results in higher CCRcv, PPVcv and
NPVcv.
Our overall conclusion from these comparisons is that joint modelling of the spatiotempo-
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ral structure in the images and the complexity in the decision boundary that is afforded by
the covariates entering the GNLM model non-linearly and interacting in a complex manner is
warranted for this data set. The images have complex structure and there is a complex relation-
ship between the image-based summary statistics and 1-year survival. Furthermore, accounting
for the uncertainty in the summary statistics and model averaging are necessary for robust
prediction.
Results from simulation studies and sensitivity analyses can be found in the SWBM.
5. Discussion
In this paper, we propose a Bayesian joint model to predict early treatment efﬁcacy based on
QMRI data from patients with high grade gliomas. In stage I, we model the spatiotemporal
structure in the QMRI data via a multivariate pairwise difference prior model and derive sum-
mary statistics as functionals of the parameters in the posterior. In stage II, a GNLM is used
to classify each patient’s 1-year survival status with the summary statistics derived in stage I
as random predictors. The ﬁnal predictive power is evaluated by cross-validation. Compared
with previous work, our proposed joint model integrates many of the ideas that have been pre-
viously discussed. First, we extend the idea of the pairwise difference model to a multivariate
setting, and, in fact, use it in a full spatiotemporal setting. The multivariate pairwise difference
prior model accounts for spatiotemporal correlation in the images as well as the correlation
between the diffusion and perfusion images. This results in an increase in the signal-to-noise
ratio. Furthermore, data dimension reduction is realized by deﬁning subject level summary sta-
tistics. Second, by utilizing the BMARS basis, we allow a ﬂexible and complex classiﬁcation
model that can achieve high predictive power. Finally, our model accounts for the uncertainty
in the stage II covariates and for the uncertainty in model selection, resulting in more robust
predictions.
Inour analysis,wedichotomize eachpatient’s survival status at 1 year.However, theremaynot
be any substantial difference between a patient who dies 11 months after diagnosis and a patient
who dies at 13 months. Moreover, the censoring rate in the data is about 30% with a median
follow-up of 23.1 months and all censored observations are greater than 1 year. Censoring may
also play a role in the evaluation of tumour treatment efﬁcacy and dichotomizing survival may
lead to inefﬁcient estimation. We are currently building a joint imaging–survival model, where,
in stage II, we model the censored survival times explicitly.
We note here thatwe propose four summary statistics that capture information about the early
changes in ADC and RCBF due to treatment. Results show that they perform well in terms of
good prediction. We do not claim that these summary statistics capture the most, or even the
best, information. Information is always lost in data reduction. Much more research is needed
to determine how much data reduction is tolerable. Reduction to four summary statistics does
a good job, but perhaps ﬁve or six would be better. We did not attempt to use more than four
summary statistics owing to the limited sample size in the pilot study. With larger sample sizes,
less data reduction may be beneﬁcial.
Our results show that early changes in diffusion and perfusion appear to be valuable biomar-
kers for the early assessment of treatment efﬁcacy. These result are promising, albeit prelimin-
ary. The ability to predict treatment response during therapy, as opposed to waiting to assess
traditional radiologic response, has the potential to facilitate patient management and may
allow second-line or salvage therapies to begin earlier than current practice dictates. Lastly, our
model and sampling algorithm are easily extendable to more than two image types at more than
two times points with more than four summary statistics.
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